Track topics on Twitter Track topics that are important to you
A reversal agent for the P2Y12 inhibitor may soon be available after results of a new study showed immediate and sustained reversal of the antiplatelet effects of the drug.
Medscape Medical News
Original Article: Ticagrelor Reversal Agent on the HorizonNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...